Shafa Pharmaceuticals
Shaqayeq Barzegar currently holds the position of Authorized Person at Shafa Pharmaceuticals since June 2023 and serves as the Director of International Supply Chain and Logistics at Alborz Logistics since March 2023, overseeing procurement, warehousing, inventory management, and transportation for various products both domestically and internationally. Additionally, Shaqayeq operates as a GMP Consultant at NSDB Co. since March 2020 and previously worked as the Executive Quality Manager and Quality Assurance Manager at Vira Rahesh Pharmed Pharmaceutical Co. from October 2022 to March 2023 and March 2022 to March 2023, respectively. Experience also includes roles as Head of Manufacturing Department and Manufacturing Specialist at Afa Chemi, as well as working as a Pharmacist at a pharmacy and a Manufacturing Intern at Darou Pakhsh in 2018. Shaqayeq earned a PharmD degree from Mazandaran University of Medical Sciences in 2020.
This person is not in the org chart
This person is not in any teams
Shafa Pharmaceuticals
Shafa, formerly known as Iran Licensing Company, began its activity as a pharmaceuticals and hygienic manufacturing company at multiple sites in Tehran-Iran in1969. The company changed its name to “Shafa (stand for cure) Pharmaceuticals and Hygienic” company in 1979. Shafa Pharmaceuticals, a privately owned and operated manufacturing company in Iran is erecting a new state of –the- art cGMP pharmaceuticals and biopharmaceuticals facility on the outskirts of Tehran. The site will be dedicated to manufacturing of innovative branded and quality generic products. The plant, once operational would be the largest facility of its kind in Iran capable of manufacturing oral solid dosage forms (tablets, capsules, sachet, powder for oral suspension, lyophilized, effervescence), soft gel, syrup. The sterile products include eye drop, and parantral (ampoule, vials, pre-fill syringes, and cartridge) products. The facility is presently under construction, with total area under construction stand at 45,890 m2 dictated to the following disciplines: Oral solid dosage form covering 5,430m2 Sterile departments including Soft gel and syrup departments department covering 5,430 m2 Warehouse including sampling/ dispensing area 5,430 m2 Formulation & bulk production of biopharmaceutical department covering 1,600 m2 Quality control laboratories and general formulation covering 1,600 m2 Administrative floors covering 6,400 m2 Technical areas covering 20,000 m2 The estimated cost is expected to reach 250 million Euros. The bulk of the investment will be spent on procuring high technology processing equipment and machineries from European companies such as Bosch, Uhlmann, Marchesini, Fette, Glatt, Getinge, Ima, Crist, Manesty, and Pharmagel. The flooring, panelling, ducting, HVAC, BMS & EMS, including commissioning & qualification services will be provided by EU companies. The new facility is expected to be operational in 2012.